Actively Recruiting
PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
Led by Affiliated Hospital of Nantong University · Updated on 2024-01-02
68
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Concurrent chemoradiotherapy is now considered to be the standard treatment modality for esophageal cancer patients who are medically unfit for surgery. However, elderly patients have limitations in their ability to tolerate concurrent chemoradiotherapy in comparison to nonelderly patients because of medical comorbidities and reduced functional reserve of organs. Immune checkpoint inhibitors, including PD-1 inhibitor, have been used in a large number of clinical studies on esophageal cancer and have achieved certain results. PD-1 inhibitor combined with radiotherapy may be a new strategy for elderly patients with esophageal cancer. This study aims to explore the efficacy and safety of PD-1 inhibitor combined with radiotherapy in the treatment of elderly patients with esophageal cancer. PD-1 inhibitor was delivered 200mg once before radiotherapy and 200mg every 3-4 weeks after radiotherapy for one year.
CONDITIONS
Official Title
PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 70 years or above
- Treatment naive patients with pathology proven esophageal squamous cell carcinoma that was inoperable or refuse surgery and who could not tolerate concurrent chemoradiotherapy
- Stage II-IVa according to the AJCC TNM staging system
- Estimated survival time 6 3 months
- Karnofsky performance score 670
- Normal blood routine, liver and kidney function less than 2 times of the normal upper limit
- Without mental disorders, cooperate with treatment and follow-up
- Have fully understood this study and voluntarily signed the informed consent
You will not qualify if you...
- Esophageal bronchial fistula or esophageal mediastinal fistula
- Patients who have participated in other clinical trials before this treatment
- Severe heart, liver and/or kidney dysfunction
- Serious infectious diseases
- Esophageal cancer who has received surgery, chemotherapy, PD-1 inhibitor or radiotherapy
- Severe autoimmune disease
- Relapse disease or distant metastasis
- Combined with other malignant tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China, 226001
Actively Recruiting
Research Team
Y
Yu Weiwei
CONTACT
S
Song Haotian
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here